Identification
- Summary
Nystatin is a polyene ionophore antifungal used to treat cutaneous, mucocutaneous, and gastrointestinal mycotic infections, particularly those caused by Candida species.
- Brand Names
- Flagystatin, Mycostatin, Nyaderm, Nyamyc, Nystop, Viaderm Kc
- Generic Name
- Nystatin
- DrugBank Accession Number
- DB00646
- Background
Nystatin is a polyene antifungal drug that has broad-spectrum fungicidal and fungistatic activity against a number of yeasts and fungi, most notably Candida species.8 It is one of the most effective antifungal agents synthesized by bacteria, in this case a strain of Streptomyces noursei,13 and is closely related to amphotericin B, differing only slightly in structure.2 Nystatin has a greater antifungal activity than amphotericin B - parenterally administered nystatin, however, is associated with significant toxicity and is not available in a formulation appropriate for systemic use.2 As it undergoes very little absorption following oral or topical administration, nystatin's efficacy is limited to the treatment/prevention of cutaneous, mucocutaneous, and gastrointestinal fungal infections.8,9
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
Structure for Nystatin (DB00646)
- Weight
- Average: 926.107
Monoisotopic: 925.503499959 - Chemical Formula
- C47H75NO17
- Synonyms
- Nistatina
- NYS
- Nystatin
- Nystatine
- Nystatinum
Pharmacology
- Indication
Nystatin is available in oral formulations for the treatment and/or prevention of oral candidiasis (a.k.a. thrush), intestinal candidiasis, and anal candidiasis.8,9 It is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infections.9 A combination product containing nystatin alongside neomycin, gramicidin D, and triamcinolone (Viaderm K.C.®) is indicated in the treatment of corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae.10 It is also available in combination with metronidazole for the treatment of mixed infections due to Trichomonas vaginalis and Candida albicans.13
Nystatin is also sometimes used off-label for the prevention of invasive candidiasis in low birth weight neonates,4 though it is generally reserved as a second-line option after fluconazole.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prophylaxis of Anal candidiasis ••• ••• •••••• Treatment of Anal candidiasis ••• ••• •••••• Treatment of Candidiasis, cutaneous •••••••••••• •••••• •••••••• Prophylaxis of Candidiasis, invasive ••• ••••• •••••••• ••• ••••• •••••• Prophylaxis of Intestinal candidiasis ••• ••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Nystatin is an antifungal that is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It exerts its antifungal effects via disruption of the fungal cell membrane. Resistance to nystatin is minimal in Candida albicans, but tends to develop in other species of Candida.8 Nystatin carries no significant activity against bacteria, protozoa, or viruses. It carries significant systemic toxicity and is currently unavailable in a formula appropriate for systemic use - its efficacy is currently restricted, therefore, to topical, oral, and gastrointestinal infections.2
- Mechanism of action
Nystatin is a channel-forming ionophore, meaning it exerts its therapeutic effect via formation of a membrane-spanning pore in the fungal plasma membrane.5 The formation of this pore results in a change in membrane permeability that allows for leakage of intracellular contents and the subsequent disruption of electrochemical gradients necessary for proper cell function.8,2 Selectivity for fungal cells over mammalian cells is due to nystatin’s greater binding affinity for ergosterol, a key sterol found in fungal cell walls, as opposed to its mammalian counterpart, cholesterol.6
Target Actions Organism AErgosterol binderCandida albicans - Absorption
Systemic absorption of nystatin is minimal following oral administration,8 and no detectable plasma concentrations are attained following topical or vaginal administration.12
- Volume of distribution
Nystatin is not absorbed into the systemic circulation8 and thus does not undergo distribution.
- Protein binding
Nystatin is not absorbed into the systemic circulation8 and is therefore not subject to plasma protein binding.
- Metabolism
Because nystatin undergoes little-to-no systemic absorption it is not metabolized to any appreciable extent.8
- Route of elimination
The majority of orally administered nystatin is eliminated unchanged in the feces.8
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The oral LD50 in rats is 10 g/kg.11 There have been no reports of serious toxic effects following overdosage of nystatin - doses in excess of five million units daily have resulted in nausea and gastrointestinal upset with no other associated effects.8
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbrisentan The excretion of Ambrisentan can be decreased when combined with Nystatin. Asunaprevir The excretion of Asunaprevir can be decreased when combined with Nystatin. Atogepant The serum concentration of Atogepant can be increased when it is combined with Nystatin. Atorvastatin The excretion of Atorvastatin can be decreased when combined with Nystatin. Axitinib The excretion of Axitinib can be decreased when combined with Nystatin. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Nystatin dihydrate Not Available Not Available VXWFKTGGEJLHPP-WFCLXGQZSA-N - Product Images
- International/Other Brands
- Adiclair (Ardeypharm) / Afunginal (Euro Generics) / Biofanal (Pfleger) / Candacide (Be-Tabs Pharmaceuticals) / Candermil (LKM) / Candex (Square) / Candidias (Fabra) / Candistat (Ambalal Sarabhai Enterprises) / Candistin (Pharos) / Canstat (Aspen Pharmacare) / Cazetin (Ifars) / Diaper NZ (Cheminter) / Dipni (Omega) / Enystin (Kalbe) / Fukangning (Deyer) / Fungatin (Ferron) / Fungicidin Leciva (Zentiva) / Fungistin (Beximco) / Fungostatin (Nobel) / Funistatin (Nobel) / Gynostatin (Iqfarma) / Kandistatin (Metiska) / Kenalon (Ta Fong) / Lederlind (Riemser) / Ledernyst (Riemser) / Lystin (Biolab) / Nilstat (Glenmark) / Nyaderm (Taro) / Nystan (Bristol Myers Squibb)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Mestatin Cream 25000 unit / g Vaginal Medic Laboratory LtÉe 1980-12-31 1996-09-09 Canada 
Mycostatin Oral Suspension 100000iu Liquid 100000 unit / mL Oral Squibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc. 1972-12-31 2003-07-28 Canada Mycostatin Oral Tab 500000iu Tablet 500000 unit Oral Squibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc. 1955-12-31 2002-07-30 Canada Mycostatin Vaginal Crm 25000unit Cream 25000 unit / g Vaginal Squibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc. 1973-12-31 2005-08-01 Canada Nadostine Sus 100000iu/ml Suspension 100000 unit / mL Oral Lab Nadeau LtÉe, Division Of Technilab Inc. 1974-12-31 2004-08-03 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dom-nystatin Suspension Suspension 100000 unit / mL Oral Dominion Pharmacal 1998-08-05 Not applicable Canada Ftp-nystatin Solution / drops 100000 unit / mL Oral Ftp Pharmacal Inc. 1998-10-09 2004-08-03 Canada Jamp-nystatin Oral Suspension USP Suspension 100000 unit / mL Oral Jamp Pharma Corporation 2015-01-09 Not applicable Canada Klayesta Powder 100000 U/1g Topical Epic Pharma, LLC 2023-04-14 Not applicable US 
Mycostatin Cream 100000 [USP'U]/1g Topical E.R. Squibb & Sons, L.L.C. 2007-01-01 2007-06-30 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Candistatin Topical Powder - 100000 Unit/g Powder 100000 unit / g Topical Bristol Myers Squibb 1996-12-31 2008-04-25 Canada Mycostatin Crm 100000unit/gm Cream 100000 unit / g Topical Squibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc. 1970-12-31 2006-09-06 Canada Mycostatin Ont 100000iu/gm Ointment 100000 unit / g Topical Squibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc. 1955-12-31 2002-07-30 Canada Mycostatin Topical Pwr 100,000units/gm Powder 100000 unit / g Topical Convatec, Division Of Bristol Myers Squibb Canada Co. 1994-12-31 2008-11-12 Canada Nadostine Crm 100000iu/gm Cream 100000 unit / g Topical Lab Nadeau LtÉe, Division Of Technilab Inc. 1974-12-31 2004-08-03 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image APOLIND WUNDBAL M NYSTATIN Nystatin (70000 IU/g) + Zinc oxide (492 mg/g) Suspension Oral 2006-07-01 Not applicable Germany 
APOLIND WUNDBAL M NYSTATIN Nystatin (70000 IU/g) + Zinc oxide (492 mg/g) Suspension Oral 2006-07-01 Not applicable Germany BABYLIND MEDICADA® CREMA TÓPICA. Nystatin (100 %) + Zinc oxide (20 g) Cream Topical LABORATORIOS DEMAC LTDA. 2020-12-16 Not applicable Colombia 
BABYSKIN® N CREMA Nystatin (2.2727 g) + Zinc oxide (40 g) Cream Topical ALTEA FARMACEUTICA S.A. 2009-06-24 Not applicable Colombia CREMA N°. 4® MEDICADA Nystatin (10000000 millions) + Zinc oxide (20 g) Cream Topical TECNOFAR TQ S.A.S 2006-11-10 Not applicable Colombia - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image FIRST BXN Mouthwash Nystatin (6.75 mg/1mL) + Diphenhydramine hydrochloride (0.84 mg/1mL) + Lidocaine hydrochloride (6.75 mg/1mL) Kit Oral CutisPharma, Inc 2009-09-08 Not applicable US FIRST Dukes Mouthwash Compounding Nystatin (0.6 g/0.6g) + Diphenhydramine hydrochloride (0.525 g/0.525g) + Hydrocortisone (0.06 g/0.06g) Kit Oral CutisPharma, Inc. 2010-12-15 Not applicable US FIRST Marys Mouthwash Compounding Nystatin (1.2 g/1.2g) + Diphenhydramine hydrochloride (0.45 g/0.45g) + Hydrocortisone (0.06 g/0.06g) + Tetracycline hydrochloride (1.5 g/1.5g) Kit Oral CutisPharma, Inc. 2010-12-15 Not applicable US MIKOSTATIN 100.000 I.U./ML ORAL SÜSPANSİYON 48 ML Nystatin (100000 i.u./ml) Oral Deva Holding A.S. 2013-01-29 Not applicable Turkey 
Categories
- ATC Codes
- D01AA01 — Nystatin
- D01AA — Antibiotics
- D01A — ANTIFUNGALS FOR TOPICAL USE
- D01 — ANTIFUNGALS FOR DERMATOLOGICAL USE
- D — DERMATOLOGICALS
- G01AA — Antibiotics
- G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
- G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
- G — GENITO URINARY SYSTEM AND SEX HORMONES
- A07AA — Antibiotics
- A07A — INTESTINAL ANTIINFECTIVES
- A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Alimentary Tract and Metabolism
- Anti-Infective Agents
- Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
- Antifungal Agents
- Antifungal Agents (Vaginal)
- Antifungals for Dermatological Use
- Antifungals for Topical Use
- Compounds used in a research, industrial, or household setting
- Dermatologicals
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Intestinal Antiinfectives
- Ionophores
- Lactones
- Membrane Transport Modulators
- OATP1B1/SLCO1B1 Inhibitors
- OATP1B3 inhibitors
- Polyene Antifungal
- Polyenes
- Polyketides
- Classification
- Not classified
- Affected organisms
- Fungi
Chemical Identifiers
- UNII
- W1LX4T91WI
- CAS number
- 1400-61-9
- InChI Key
- VQOXZBDYSJBXMA-NQTDYLQESA-N
- InChI
- InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33+,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
- IUPAC Name
- (1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
- SMILES
- [H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\CC\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2
References
- General References
- Akaike N, Harata N: Nystatin perforated patch recording and its applications to analyses of intracellular mechanisms. Jpn J Physiol. 1994;44(5):433-73. [Article]
- Dos Santos AG, Marques JT, Carreira AC, Castro IR, Viana AS, Mingeot-Leclercq MP, de Almeida RFM, Silva LC: The molecular mechanism of Nystatin action is dependent on the membrane biophysical properties and lipid composition. Phys Chem Chem Phys. 2017 Nov 15;19(44):30078-30088. doi: 10.1039/c7cp05353c. [Article]
- Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16. [Article]
- Yamasaki M, Tamura N, Nakamura K, Sasaki N, Murakami M, Rajapakshage W, Kumara B, Tamura Y, Lim SY, Ohta H, Takiguchi M: Effects and mechanisms of action of polyene macrolide antibiotic nystatin on Babesia gibsoni in vitro. J Parasitol. 2011 Dec;97(6):1190-2. doi: 10.1645/GE-2799.1. Epub 2011 Jul 14. [Article]
- Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [Article]
- Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S: A Drug-drug Interaction Between Cyclosporine and Nystatin. Clin Ther. 2018 Apr;40(4):660-662. doi: 10.1016/j.clinthera.2018.02.008. Epub 2018 Mar 16. [Article]
- FDA Approved Drug Products: Nystatin oral suspension [Link]
- DPD Approved Drugs: Nystatin [Link]
- DPD Approved Drugs: Viaderm K.C.® [Link]
- ThermoFisher Scientific: Nystatin MSDS [Link]
- MedSafe NZ: Nystatin [Link]
- DPD Approved Drugs: Flagystatin® vaginal ovules [Link]
- External Links
- Human Metabolome Database
- HMDB0014784
- KEGG Drug
- D00202
- KEGG Compound
- C12155
- PubChem Compound
- 11953884
- PubChem Substance
- 46504780
- ChemSpider
- 23078586
- 7597
- ChEBI
- 473992
- ChEMBL
- CHEMBL450895
- ZINC
- ZINC000253387941
- Therapeutic Targets Database
- DAP000879
- PharmGKB
- PA450666
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Nystatin
- FDA label
- Download (776 KB)
- MSDS
- Download (72.5 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Health Services Research Renal Failure, Chronic Renal Failure 1 4 Completed Prevention Candidiasis / Critically Ill Patients / Fungal Prophylaxis / Surgery 1 4 Completed Prevention Systemic Fungal Infections 1 4 Completed Prevention Very Low Birthweight Infants 1 4 Completed Treatment Photochemotherapy Reaction 1
Pharmacoeconomics
- Manufacturers
- Bayer pharmaceuticals corp
- Bristol myers squibb co
- Alpharma us pharmaceuticals division
- Lederle laboratories div american cyanamid co
- Actavis mid atlantic llc
- Altana inc
- Perrigo new york inc
- Taro pharmaceuticals usa inc
- Teva pharmaceuticals usa inc
- Vintage pharmaceuticals llc
- Westwood squibb pharmaceuticals inc
- Bristol myers squibb
- Barlan pharmacal co inc
- Dava pharmaceuticals inc
- Paddock laboratories inc
- Coastal pharmaceuticals inc
- Kv pharmaceutical co
- Par pharmaceutical inc
- Upsher smith laboratories inc
- X gen pharmaceuticals inc
- Warner chilcott co llc
- Apothecon inc div bristol myers squibb
- Glenmark generics inc usa
- Bausch and lomb pharmaceuticals inc
- E fougera div altana inc
- Morton grove pharmaceuticals inc
- Pharmaderm div altana inc
- Pharmafair inc
- Roxane laboratories inc
- Vintage pharmaceuticals inc
- Vistapharm inc
- Wockhardt eu operations (swiss) ag
- Savage laboratories inc div altana inc
- Mutual pharmaceutical co inc
- Quantum pharmics ltd
- Sandoz inc
- Usl pharma inc
- Watson laboratories inc
- Holland rantos co inc
- Odyssey pharmaceuticals inc
- Packagers
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Aidarex Pharmacuticals LLC
- Apothecon
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Bausch & Lomb Inc.
- Bryant Ranch Prepack
- Cardinal Health
- Contract Pharm
- Cutis Pharma Inc.
- Dept Health Central Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Duramed
- E. Fougera and Co.
- E.R. Squibb and Sons LLC
- Gallipot
- Glenmark Generics Ltd.
- Major Pharmaceuticals
- Medisca Inc.
- Metrics Inc.
- Midlothian Labs
- Murfreesboro Pharmaceutical Nursing Supply
- Mutual Pharmaceutical Co.
- Novopharm Ltd.
- Nycomed Inc.
- Odyssey Pharmaceuticals Inc.
- Paddock Labs
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- PD-Rx Pharmaceuticals Inc.
- PEDiNOL
- Perrigo Co.
- Pharmaceutical Association
- Pharmaceutics International Inc.
- Pharmedix
- Physicians Total Care Inc.
- Pliva Inc.
- Precision Dose Inc.
- Preferred Pharmaceuticals Inc.
- Qualitest
- Rebel Distributors Corp.
- Sandoz
- Savage Labs
- Stat Scripts LLC
- Taro Pharmaceuticals USA
- Teva Pharmaceutical Industries Ltd.
- USL Pharma Inc.
- Vintage Pharmaceuticals Inc.
- Vistapharm Inc.
- Wockhardt Ltd.
- Xactdose Inc.
- X-Gen Pharmaceuticals
- Dosage Forms
Form Route Strength Cream Topical 100000 IU/g Ointment Topical 100000 IU/g Suspension Oral 100000 IU/g Tablet, film coated Oral 500000 IU Gel Topical 100000 IU/g Suspension Oral Tablet Vaginal 100000 UI Tablet, sugar coated Oral 500000 IU/1 Kit Topical 25 G Suspension Oral 000 UI Paste Topical Cream Topical 100000 USP Ointment Topical 100000 USP Suspension Oral 100000 USP Gel Topical 250000 USP Paste Topical 100000 USP Cream Topical Solution / drops; suspension / drops 100 IU/ML Suspension Oral 24 doz Suspension Oral 100000 IU/ML Kit Oral Solution / drops Oral 100000 unit / mL Powder, for suspension Oral 100000 iu/ml Suspension Oral 1710.623 mg Tablet, coated Oral 500000 IU Suspension Oral 100 IU/L Paste Topical 100000 IU/g Cream Vaginal Insert Vaginal Insert Vaginal 500 mg Suspension Oral 30 ml Paste Topical Cream Vaginal 100000 IU/g Pill 500000 U Powder Topical 100000 [USP'U]/1g Suspension Oral 100000 UI/ML Tablet, film coated Oral Suspension Oral Ointment Topical Liquid Oral 100000 unit / mL Powder Topical 100000 unit / g Suspension Oral 100000 unit / mL Tablet Vaginal 100000 unit Tablet Oral 500000 unit / tab Cream Vaginal 100000 unit / g Tablet Vaginal 100000 unit / tab Suspension Oral 0 IU Tablet, coated Oral Insert Vaginal 100 IU Tablet Vaginal 100 IU Suspension Oral 10000000 IU Suspension Oral 2000 mg Suspension Oral 1.94 g Cream Topical 10 millions Insert Vaginal 100000 IU Tablet, coated Oral 50000000000 IU Tablet Vaginal 000 UI Suspension Oral 100 IU/ML Cream Vaginal 25000 unit / g Suppository Vaginal Kit Topical 100000 U/1g Suspension Oral 100000 IU Cream Oral; Topical 100000 [USP'U]/1g Cream Topical 100000 1/1g Cream Topical 100000 U/1g Cream Topical 100000 [USP'U]/1g Cream Topical 100000 mg/1g Insert Vaginal 100000 [USP'U]/1 Ointment Topical 100000 U/1g Ointment Topical 100000 1/1g Ointment Topical 100000 [USP'U]/1g Powder Topical 100000 1/1g Powder Topical 100000 Powder, for suspension Oral 5000 Solution / drops; suspension / drops Suspension Oral 100000 [USP'U]/1mL Suspension Oral 100000 Suspension Oral 100000 [USP'U]/15mL Suspension Oral 100000 [iU]/1mL Suspension Oral 100000 U/1mL Suspension Oral 500000 [USP'U]/5mL Tablet Vaginal Tablet, coated Oral 500000 [USP'U]/1 Tablet, film coated Oral 500000 [USP'U]/1 Tablet, sugar coated Oral Powder Oral Cream Topical Ointment Topical Solution Oral 100000 [USP'U]/1mL Tablet, sugar coated Oral 500000 IU Tablet Oral Powder Topical 100000 U/1g Tablet Vaginal 100000 units Ointment Auricular (otic) Kit Topical 100000 [USP'U]/1g Suspension Oral 500000 u/5ml Capsule Vaginal 35000 iu Cream Topical 100000 unit / g Ointment Topical 100000 unit / g Tablet Oral 500000 unit Cream Topical 2.059 g Suppository Vaginal Capsule Oral Suspension Oral 100000 UNITS/1ML Tablet, sugar coated Oral 500000 UNITS Tablet Vaginal 100000 iu Capsule Vaginal Tablet Vaginal - Prices
Unit description Cost Unit Nystatin 10 billion unit powder 3014.1USD each Nystatin 5 billion unit powder 2096.1USD each Nystatin 2 billion unit powder 1116.9USD each Nystatin 1 billion unit powder 452.08USD each Nystat-rx 5 billion unit powder 447.0USD each Nystatin 500 million unit powder 130.75USD each Pedi-Dri 100000 unit/gm Powder 56.7 gm Bottle 105.87USD bottle Nystatin 150mu Bottle 94.5USD bottle Nystatin 150 million unit powder 42.25USD each Nystatin 150000000 unit powder 42.0USD each Nystatin Nystatin Powder 50 Million unit Bottle 39.99USD bottle Mycostatin 100000 unit/gm Powder 15 gm Bottle 36.99USD bottle Nystop 100000 unit/gm Powder 15 gm Bottle 29.99USD bottle Nystatin 50 million unit powder 19.75USD each Nystatin 100000 unit/gm Ointment 15 gm Tube 12.99USD tube Nystatin 100000 unit/gm Cream 15 gm Tube 6.5USD tube Nystatin 100000 unit tablet 5.29USD tablet Nystatin vaginal tablet 5.0USD tablet Pedi-dri topical powder 1.82USD g Nystop 100000 unit/gm powder 1.6USD g Nystatin 500000 unit tablet 0.71USD tablet Nystatin 500000 unit oral tablet 0.68USD tablet Mycostatin 500000 unit orl tablet 0.48USD tablet Nystatin 100000 unit/ml Suspension 0.25USD ml Ratio-Nystatin 500000 unit Tablet 0.25USD tablet Nystatin 100000 unit/gm cream 0.1USD g Pms-Nystatin 100000 unit/ml Suspension 0.05USD ml Ratio-Nystatin 100000 unit/ml Suspension 0.05USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 160 °C (decomposes) MSDS water solubility 360 mg/L (at 24 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 0.5 Not Available - Predicted Properties
Property Value Source Water Solubility 0.086 mg/mL ALOGPS logP -3.1 ALOGPS logP -1.9 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 3.61 Chemaxon pKa (Strongest Basic) 9.11 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 17 Chemaxon Hydrogen Donor Count 12 Chemaxon Polar Surface Area 319.61 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 243.55 m3·mol-1 Chemaxon Polarizability 100.62 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8641 Blood Brain Barrier - 0.9581 Caco-2 permeable - 0.741 P-glycoprotein substrate Substrate 0.5182 P-glycoprotein inhibitor I Non-inhibitor 0.814 P-glycoprotein inhibitor II Non-inhibitor 0.6721 Renal organic cation transporter Non-inhibitor 0.96 CYP450 2C9 substrate Non-substrate 0.8313 CYP450 2D6 substrate Non-substrate 0.867 CYP450 3A4 substrate Non-substrate 0.5273 CYP450 1A2 substrate Non-inhibitor 0.916 CYP450 2C9 inhibitor Non-inhibitor 0.9374 CYP450 2D6 inhibitor Non-inhibitor 0.9354 CYP450 2C19 inhibitor Non-inhibitor 0.9243 CYP450 3A4 inhibitor Non-inhibitor 0.931 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.987 Ames test Non AMES toxic 0.8992 Carcinogenicity Non-carcinogens 0.9731 Biodegradation Not ready biodegradable 0.8601 Rat acute toxicity 2.1245 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9462 hERG inhibition (predictor II) Non-inhibitor 0.8971
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Yes
Binder
References
- Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
- Gene Name
- SLCO1B3
- Uniprot ID
- Q9NPD5
- Uniprot Name
- Solute carrier organic anion transporter family member 1B3
- Molecular Weight
- 77402.175 Da
References
- Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]
Drug created at June 13, 2005 13:24 / Updated at April 18, 2024 13:02